Objective: Treatment decision-making in bipolar II disorder is complex due to limited evidence on treatment efficacy and potentially burdensome side-effects of options. Thus, involving patients and negotiating treatment options with them is necessary to ensure that final treatment decisions balance both clinician and patient preferences. This study qualitatively explored clinician views on (a) effective treatment decision-making, unmet patient needs for (b) decision-support and (c) information. Method: Qualitative semi-structured interviews with 20 practising clinicians (n = 10 clinical psychologists, n = 6 general practitioners, n = 4 psychiatrists) with experience treating adult outpatients with bipolar II disorder were conducted. Interviews were audiotaped, transcribed verbatim and analysed thematically using framework methods. Self-report professional experience, and clinician preferences for patient decision-making involvement were also assessed. Results: Qualitative analyses yielded two inter-related themes: (a) challenges and barriers to decision-making and (b) facilitators of clinician decision-making. Symptom severity, negative family attitudes, system-based factors, and information gaps were thought to pose challenges to decision-making. By contrast, decision-making was supported by patient information, family involvement and patient-centredness, and a strong therapeutic relationship. Clinician views varied depending on their professional background (medical vs clinical psychologist), patient involvement preferences, and whether the clinician was a bipolar specialist. Conclusions: Whilst clinicians uniformly recognise the importance of involving patients in informed treatment decision-making, active patient participation is hampered by unmet informational and decision-support needs. Current findings inform a number of bipolar II disorder-specific, clinician-endorsed strategies for facilitating patient decision-making, which can inform the development of targeted patient decisionsupport resources for use in this setting.
Introduction
In shared treatment decision-making (SDM), the clinician and patient (and others, e.g. family) share their respective knowledge and expertise regarding the different treatment options, and deliberate on the benefit-costs of these in relation to the patients' values (Charles, Gafni, & Whelan, 1997 . Critically, the final decision in SDM would incorporate both parties' preferences. Not only does SDM support patient autonomy and informed decision-making, it is consistent with many patients' preferences for information and involvement in their own mental health treatment decisions (Drake, Cimpean, & Torrey, 2009; Duncan, Best, & Hagen, 2010; Fisher, Manicavasagar, Sharpe, Laidsaar-Powell, & Juraskova, 2016) . Thus, SDM has attracted increasing attention in the literature and in clinical practice for its applicability to many mental health conditions (Drake et al., 2009; Hamann & Heres, 2014; Hamann, Leucht, & Kissling, 2003; Perestelo-Perez, Gonzalez-Lorenzo, PerezRamos, Rivero-Santana, & Serrano-Aguilar, 2011) .
SDM may particularly benefit patient outcomes in chronic mental illnesses, which rely on patients adopting a selfmanagement approach to prevent illness symptoms (Deegan & Drake, 2006) . Bipolar disorder is one such illness where shared approaches to decision-making and management have been linked to improved outcomes, such as treatment adherence and satisfaction with care (Berk, Berk, & Castle, 2004) . Although SDM has value in both bipolar I and II disorders, SDM may be particularly important and challenging in bipolar type II (BPII), given that treatment options are more finely balanced between clinician and patient preferences. This is due to: the absence of psychosis in BPII (Parker et al., 2013) , lack of psychosocial impairment during hypomania (Judd et al., 2005) , and limited published BPII-specific treatment guidelines which draw on a relative paucity of research to advise first-line moodstabilising medications (i.e., lithium, lamotrigine, quetiapine) together with adjunctive psychological treatment (i.e., cognitive behavioural therapy, group psycho-education; Fountoulakis, 2015a Fountoulakis, , 2015b Gitlin & Frye, 2012; Yatham et al., 2013) .
Despite the importance of collaborative approaches to decision-making, many patients with bipolar disorder continue to experience low levels of involvement in shared treatment decision-making despite expressing a preference for it (Fisher, Manicavasagar, Kiln, & Juraskova, 2016; Liebherz, Tlach, Här-ter, & Dirmaier, 2015) . This mismatch between preferred and experienced levels of patient involvement in bipolar disorder may not only compromise patient outcomes (De las Cuevas, Peñate, & de Rivera, 2014a; Park et al., 2014) , but also points to barriers to achieving SDM in this population. There remains a dearth of research on SDM in bipolar disorder , especially qualitative investigations of key clinician, patient, and family perspectives. In order to maximise patient involvement in treatment decision-making, in line with their preferences, challenges and enablers to this process need to be examined.
Only one qualitative study has investigated the facilitators of collaboration between clinicians and patients in bipolar disorder specifically (Sajatovic et al., 2005) . This study identified patient-related barriers, such as symptoms, communicative difficulties, as well as clinician-related barriers, such as poor empathy and listening, and discounting patient concerns. Also identified were several patient-related facilitators, such as open communication and family involvement, and clinician-related facilitators, such as meaningful discussion of patient problems (Sajatovic et al., 2005) . However, this study did not ask specifically about treatment decision-making, and included only patient perspectives. In fact, no existing studies have explored the views and experiences of clinicians on the process of treatment decision-making in bipolar disorder , in contrast to several studies on depression (McMullen, 2012; Simmons, Hetrick, & Jorm, 2013) and schizophrenia (Farrelly et al., 2016; Hamann et al., 2015; Seale, Chaplin, Lelliott, & Quirk, 2006) . This represents a significant gap in the literature as both patient-and clinician-initiated behaviours contribute to overall SDM levels within consultations (Fukui et al., 2014) . Thus, clinicians treating BPII have a responsibility to carefully negotiate the various treatment options with patients to ensure that the final treatment decision is shared and balances both their own and their patient's preferences and values.
This study aimed to qualitatively explore clinicians' views and experiences of BPII treatment decision-making with patients in an outpatient setting. Consistent with the Ottawa decision-support framework (Jacobsen & O'Connor, 1999) , which posits the link between decisional needs, quality of decision-making, and tailoring of decision-support this study had two principle aims. These were to elucidate: (a) the challenges clinicians encounter in meeting patient needs for decision-support and information; (b) the perceived barriers and facilitators to effective treatment decision-making.
Methods

Participants
Eligible clinicians (N = 26) were those who were currently practising, and had experience in treating adults diagnosed with bipolar II disorder (BPII) within the outpatient setting. This included both medical and non-medical clinicians (i.e., psychiatrists, GPs, and clinical psychologists) working across general practice and specialist care. Three recruitment methods were utilised: (a) Clinicians affiliated with the Black Dog Institute (BDI, a clinical service specialising in the assessment and treatment of mood and bipolar disorders); (b) clinicians attending BDI-organised professional development workshops; (c) clinicians signed up to receive BDI e-newsletters. Purposive sampling was used to obtain maximum variation on clinician characteristics such as years of clinical practice and professional specialty.
Recruitment continued until data saturation (three consecutive interviews revealing no new information) was achieved (Bowen, 2008) . All aspects of the study received ethics approval from The University of Sydney Human Research Ethics Committee, and complied with the Code of Ethics of the World Medical Association (Declaration of Helsinki; World Health Organisation, 1996) . then explained the study rationale to clinicians and obtained verbal consent to post/email a study pack to them, which contained an information sheet and consent form, and preinterview questionnaire. Participants were sent two reminders, 1 and 2 weeks after the study pack was sent to them. Once the completed questionnaire and consent form were received, a one-off telephone interview was arranged.
Qualitative Data Collection
A purpose-designed, semi-structured interview protocol was based on: widely-cited models of SDM (Charles et al., 1997 (Charles et al., , 1999 Elwyn et al., 2012) , the Ottawa decisional support framework (Jacobsen & O'Connor, 1999; O'Connor et al., 1998; Stacey et al., 2008) , and previous qualitative studies of treatment decision-making in the mental health (e.g., unipolar depression; Simon, Loh, Wills, & Härter, 2007) and medical settings (e.g., cancer; Laidsaar-Powell et al., 2016a) .
In this article we report on clinician-perceived challenges to decision-making about BPII treatment, as well as strategies for improving this process. Other results from this qualitative study, such as clinician-patient-family involvement and the nature of treatment decisions in this setting, will be reported elsewhere.
Statement of Reflexivity
The first author (AF), who conducted all interviews, is a female PhD student with a background in clinical health psychology and SDM, and experience in conducting qualitative interviews across a number of patient populations (e.g., bipolar disorder, cancer, and traumatic brain injury). Although not trained as a clinical psychologist, AF has developed specialised clinical knowledge in mood and bipolar-related disorders through an Honours degree in Psychology and attendance at professional development workshops for clinical psychologists, GPs, and allied health professionals. During and immediately after each interview, AF wrote memos on any initial impressions and noteworthy remarks in order to maintain reflexivity and an awareness of potential personal biases throughout the interview process.
Quantitative Measures
Clinician preferences for their own and others' (i.e., patients/ family) decision-making involvement were assessed using an adapted version of the Control Preferences Scale (CPS, Degner et al., 1997; Janz et al., 2004; Nolan et al., 2005) . This selfreport, two-item scale measured involvement preferences both in dyadic (clinician-patient) and triadic scenarios (clinicianpatient-family). For both dyadic and triadic scenarios, participant preferences can be categorised as active (fully patient-led, or patient-led with clinician[/family] involvement), shared (equal clinician-patient[−family] involvement), or passive (fully clinician-led or clinician-led with patient[/family] involvement). The CPS has been used to evaluate physician perceptions of patient involvement in treatment decisionmaking (Janz et al., 2004) , and in outpatient samples including bipolar disorder (Adams, Drake, & Wolford, 2007; De las Cuevas, Peñate, & de Rivera, 2014b; De las Cuevas et al., 2014a) .
Demographic, clinical, and professional characteristics (e.g., age, gender, years in clinical practice, typical patient presentation, and treatment types) were collected via a purpose-designed self-report questionnaire. Participants also indicated whether, and how often family members attended consultations.
Data Analysis
Descriptive and frequency analyses of questionnaire data were conducted using SPSS version 22. Interviews were audiorecorded and professionally transcribed. The interviews were then thematically analysed (Braun & Clarke, 2006) using framework methods as outlined by Ritchie, Lewis, Nicholls, and Ormston (2013) . To ensure methodological rigour, a proportion of the transcripts (20%) were cross-coded by a second co-author (RL-P) and discrepancies discussed and resolved before proceeding with coding the entire dataset. Second, the thematic map was developed in consultation with two coauthors, who have expertise in treatment decision-making and qualitative analysis. Table 1 summarises clinicians' demographic and clinical characteristics. Of the 26 clinicians who were approached and agreed to participate, 20 completed both the questionnaire and interview (76.9% response rate). Recruitment was balanced across clinical psychologists (n = 10) and medical clinicians (psychiatrists, GPs; n = 10). Interviews ranged from 21 to 51 min in length (M = 34 min).
Results
Participant Characteristics
All clinician groups reported extensive professional experience ; almost all clinicians (90%) practised in metropolitan areas. Half of psychiatrists (50%) and most clinical psychologists (70%) reported specialisation in the assessment/treatment of bipolar and other mood disorders; most GPs (83%) reported no mental health speciality. All clinicians indicated that medication and adjunctive psychological-based interventions typically made up their patients' treatment. Regarding preferred patient involvement, all except one clinician preferred patient (or family)-led or SDM in both dyadic (clinicianpatient) and triadic (clinician-patient-family) consultations (Table 1) .
Qualitative Findings
Qualitative analyses yielded two inter-related themes, each comprising several subthemes: (a) Challenges and barriers to decision-making and (b) facilitators of clinician decision-making. Illustrative patient and family quotes are presented in Tables 2  and 3 .
Theme 1: Challenges and Barriers to Decisionmaking Theme 1 (Table 2 ) encompassed clinician-perceived challenges to decision-making about BPII treatment. Challenges were diverse, spanning patient-related, clinician-related, and familyrelated factors as well as shortcomings of the healthcare system and available patient information.
Patient-related
A large proportion of clinicians referred to the negative impact of BPII symptoms on treatment decision-making. Both hypomanic and depressive symptoms were associated with limited "chances of making correct decisions," a skewed "frame of reference" (insight), "regret [about] decisions," and poor "concentration to make decisions" (clinical psychologist 318, Table 2 ).
Several clinicians noted that some patients held a priori treatment preferences, based on "preconceived ideas and stigma attached to taking medication" (GP 332, Table 2 ). Clinicians reported that these presented an obstacle to decision-making because patients with preconceptions about medications (e.g., lithium, Sodium Valproate) were often reluctant to commence them, or made "decisions in favour of psychological support" over pharmacological approaches (GP 332, Table 2 ).
Clinician-related
Almost half of clinicians noted potentially unhelpful clinician behaviours that impeded decision-making. These included: a lack of open and honest communication (about medication options/outcomes), inadequate expertise, a lack of rapport or patient trust, and being "very directive" with limited patient input (clinical psychologist 319, Table 2 ). An overly directive (paternalistic) approach was linked to a power imbalance between the patient and their clinician. Inadequate rapport or trust, and poor communication were associated with limited time with the patient, and clinicians being over-familiar with medications (due to highly specialised knowledge), respectively.
Negative Family Influences
Over half of clinicians, especially psychologists, reported family behaviours or attitudes that were detrimental to decision-making. The most commonly expressed attitude was the family's reluctance "to accept the diagnosis and…that the medication is required" (GP 332, Table 2 ). These family attitudes/behaviours resulted in patients being reluctant to commence treatment, prematurely discontinue medication, or be less successful at implementing psychological strategies. Specifically, some family (especially parents) were reported to undermine the patient's autonomy, by becoming "overly-involved" or "taking on too much" in a patient's treatment decision-making (psychiatrist 307, Table 2 ).
System-based Challenges/Barriers
Almost half of clinicians noted system-related barriers to decision-making. These included: poor access and affordability of specialist services (psychologists/psychiatrists), time constraints during consultations, and a lack of multidisciplinary communication or coordination between clinicians with different professional training. A lack of accessibility and affordability reportedly led to patients prematurely discontinuing psychological treatment, or limiting available options (clinical psychologist 308, Table 2 ). Consultations perceived as excessively short reportedly led to lower patient satisfaction due to reduced continuity of care and more prescriptive decision-making where "they've just been given the next script" without any meaningful discussion with the patient (clinical psychologist 304, Table 2 ).
Inadequacies in Available Patient Information
Almost half of clinicians, especially those preferring patient-led decision-making, noted gaps in current BPII patient information (both patient-sourced/clinician-provided information). A few clinicians, mainly psychologists, noted a general lack of written/online information and patient understanding of BPII illness and medication effects (especially long-term benefits/ prognosis). Two GPs/psychiatrists also noted that where medication information is available (either online or via patient factsheets), it was often "difficult to absorb" and too complicated for patients to understand (psychiatrist 328, Table 2 ). The lack of information or availability of highly technical information reportedly compromised decision-making because patients came to consultations insufficiently informed to make decisions or more likely to defer to the clinician (psychiatrist 328, Table 2 ).
Theme 2: Facilitators of Clinician Decision-making
Theme 2 (Table 3) highlighted clinician strategies for facilitating decision-making, such as patient information and education, encouraging family involvement and patient involvement, and fostering a strong therapeutic relationship. These facilitators mapped onto similar domains (e.g., patient-/clinician-related, informational and systemic) to those discussed in Theme 1. 
Making Time-Structuring Consultations
Over half of clinicians, mainly GPs/psychiatrists and clinicians with a speciality in bipolar disorders, felt that making time (e.g., scheduling longer consultations) and structuring decisionmaking over multiple consultations facilitated the treatment decision-making process. Usually, in the first consultation (which sometimes involved patient diagnosis), treatment options would be presented. Patients would then be encouraged to find out more about these options (via clinicianprovided information or independent information gathering) and deliberate them with family/friends. In a second follow-up appointment, the patient and clinician would discuss these options further and then make final treatment decisions. According to clinicians, structuring decision-making over more than one consultation engendered several patient benefits. Patients were reportedly more informed, asked more questions, had options explained more comprehensively, were more satisfied with decision-making (through feeling more involved), and had better treatment adherence (psychiatrist 307, Table 3 ). Two psychiatrists pointed out that this style of decision-making was more an option in BPII because the need to bring the illness under control quickly is not as pressing (as sometimes the case in bipolar I disorder).
Patient Information and Education Facilitating Decision-making
Several (n = 5) clinicians made reference to patient information needs and preferences (GP 325, Table 3 ). Two clinicians reported "The more they [family] can get involved in the understanding….and know, the more they are likely to make informed decisions. If they're not onside they have a much more powerful effect than any therapist has." (clinical psychologist 318) 2.4. Patient-centredness and involvement "…it's such an important part of clinical practice that the patient really feels like they've made choices about their treatment." (psychiatrist 309) "I think an individual autonomy and right to make decisions around their treatment is a really important part of recovery. That people feel empowered and in a sense guided but being able to make the final decision themselves." (psychiatrist 328) 2.5. Therapeutic relationship "…it does seem to be a bit of a question of trust. But also the trust goes the other way as you get to know a patient, I often say to patients that the aim of all of this is for you to become the expert." (psychiatrist 309) "If a client knows that you know what you're talking about, and they've got a good relationship with you I think fundamentally you enlist the relationship and just say now trust me on this one." (clinical psychologist 318) 2.6. Inter-professionalism and continuity of care "…When their initial diagnosis is made I always arrange a psychiatric referral…it gives them [patient] a chance to raise questions with someone different, to hear the information from someone who's an expert and get a different point of view…" (GP 324) "I monitor very frequently which means there's not this sense of being sent off to oblivion with some new medication and…no sense of someone watching it and monitoring it." (GP 324) that their patients with BPII had particularly strong information preferences (e.g., "hungry" for information). In order to support the development of a patient decisionmaking resource, clinicians were asked their preferences/ recommendations. All three clinician groups made recommendations; almost three quarters of clinicians made recommendations relating to content and features, and recommendations mostly came from clinicians who preferred patient-led decision-making. Clinicians uniformly felt that the optimal time of delivery for a patient decision-making resource was shortly after diagnosis, as this coincided with when patients were frequently considering their treatment options.
Regarding content, clinicians felt that information should cover a broad "spectrum of treatment options" including medication and psychological treatments. Information on treatment benefits/side-effects, rationale for medication use, and longerterm prognosis were all perceived as helpful (clinical psychologist 313, Table 3 ). Although a few clinicians placed greater importance on side-effect and safety information, one clinician felt that more information on treatment benefits and prognosis was needed. Another two clinicians indicated that including some background information on the illness (symptoms, course) was necessary, especially as treatment decisions were made in the knowledge that BPII was a life-long, remitting illness.
In terms of proposed features of decision-making resources, clinicians felt that information should be specific, easy-to-read, and free of medical jargon. Clinicians also valued evidencebased, reliable information with an Australian focus. Several clinicians endorsed including exercises to help patients consider which features of the different treatment options mattered most to them (i.e., values-clarification methods) alongside clinically-based information about options. This is because clinicians felt that values motivated decision-making, reflected the varied presentations of BPII and its treatment, and the resource would be more engaging for patients.
Several clinicians, especially those with a bipolar speciality, alluded to the supporting role of information in facilitating treatment decision-making. Clinician-provided psycho-education during consultations was valued and often supplemented patient resources providing written information. Both these forms of information reportedly enabled patients to be "more knowledgeable" about their illness and treatment options, "ask more appropriate questions about treatment," more actively "weighing up options," and have greater autonomy (psychiatrist 309, Table 3 ). One clinician also noted that such resources, when used in consultations could serve as a prompt for discussing treatment options in a structured way.
Clinician-provided psycho-education and written information resources was also thought to facilitate treatment decisionmaking in a number of ways. First, written information and the resulting knowledge potentially increases patient empowerment and optimism towards treatment (knowing that it is a treatable illness with various treatment options). Second, the provision of such information is important in dispelling common myths and misconceptions around medication (e.g., that it is addictive).
Almost half of clinicians reported benefits of patients hearing others' lived experience with BPII. Reported benefits included: greater credibility than clinician-provided information, providing realistic treatment goals for patients, reduced feelings of patient isolation, and acknowledging the variable presentations of BPII (clinical psychologist 303).
Clinician Perceptions of Family as a Resource
Many clinicians were unaware of the extent of family involvement that their patients used in making decisions, which is consistent with self-report questionnaires indicating family rarely attended consultations (M = 13% of consultations had family attend). Despite this, over half of clinicians felt that family involvement benefited treatment decision-making. Further, a third of clinicians, all of whom specialised in bipolar disorders, actively encouraged family involvement in decision-making (e.g., inviting family/significant others to attend appointments where important treatment decisions were likely to be made).
Most commonly, family who attended consultations were perceived to provide valuable informational support to both clinicians and patients. Informational support included providing additional information about the patient's illness history and symptoms, identifying problem areas and treatment targets that mattered to them and the patient, and communicating information between different clinicians if patients were unable to (e.g., due to symptoms). Family also purportedly helped to equalise potential power imbalances between the patient and clinician and provided reassurance for the patient (psychiatrist 309, Table 3 ).
Several clinicians viewed family engagement as playing an important role in facilitating patient treatment engagement. Patients were perceived as more engaged with treatment when family were involved, informed, and "on-side" with treatments. When family were not involved (and by implication, likely to be uninformed about) a patient's treatment decision-making they reportedly often challenged the validity of treatment decisions, which could lead to patient non-adherence to treatment (clinical psychologist 318, Table 3 ). Of note, the benefits of family involvement were noted more frequently by clinicians who preferred patient/family-led and/or triadic SDM (clinicianpatient-family) than those who preferred patient-led or clinician-led decision-making.
Patient-centredness and Involvement
Half of clinicians reported that involving patients was critically important to treatment decision-making, and was aligned with most patient involvement preferences (psychiatrist 309, Table  3 ). According to clinicians, the need to involve patients was well justified. Patients were seen as bringing recognised expertise to treatment decision-making due to their lived experience and treatment-relevant values. By involving patients and incorporating patient values into treatment decisions, patients reportedly were more informed about treatment choices, had increased feelings of decisional control and greater satisfaction, and better treatment adherence (both psychological strategies and medication; clinical psychologist 318, Table 3 ).
A few clinicians noted instances where they took a more directive approach in decision-making. These instances included patient preferences for minimal participation in decisions, or when patients had reduced decisional capacity (i.e., due to symptoms). Similarly, when clinicians felt that their patients' preferred option was "not good," they also saw the need to be more directive in their advice. However, most clinicians still tried to involve patients in decision-making as much as possible.
Therapeutic Relationship
Half of the clinicians, irrespective of patient involvement preferences, reported that a strong, collaborative therapeutic relationship founded on mutual trust was imperative to good treatment decision-making (psychiatrist 309, Table 3 ). Medical practitioners, in particular, felt that mutual trust facilitated the discussion of treatment options, more open and honest patient communication, and clinician-led decision-making when patient capacity was compromised (clinical psychologist 318, Table 3 ).
Other qualities which clinicians felt they needed to achieve for a "good" therapeutic relationship conducive to effective decision-making included being welcoming and open, nonjudgemental, and non-authoritarian. Clinicians emphasised the collaborative aspects of the therapeutic relationship, describing it as a "partnership" or "shared journey" between the patient and clinician. Collaboration was considered by one psychologist as a buffer against clinician-patient disagreement in treatment decisions.
Inter-professionalism and Continuity of Care
Over half of clinicians endorsed engaging different clinicians in treatment decision-making for a number of reasons. Both psychiatrists and GPs acknowledged that psychiatrists had more specialist knowledge and served as a good back-up for GPs' ongoing management of medication. Clinicians report that many patients preferred a multidisciplinary team approach, and that clinician consensus reassured patients that treatment recommendations were sound (GP 324, Table 3 ).
Despite this notion of multidisciplinary teams managing patient care, clinicians highlighted the importance of a "leading" clinician to ensure continuity of care for the patient and their family. Several clinicians perceived good continuity of care, in the form of regular appointments with the same clinician, as critical to treatment and ongoing treatment decisionmaking. Two clinicians reported practising good continuity of care by arranging frequent follow-up appointments, which allowed them to monitor the patient and encourage patients to reflect on their treatment decisions (GP 324, Table 3 ).
Discussion
This is the first known study to investigate clinician-perceived barriers and facilitators to BPII treatment decision-making. Further, clinicians gave insightful suggestions as to ways that patient decision-making could be improved. These strategies were often targeted directly to changing the discussed barriers. These findings form the basis of preliminary clinician-endorsed strategies for effective decision-making in BPII, outlined below and in Table 4 .
Structuring Consultations
More than half of clinicians, mainly GPs and psychiatrists, reportedly structured their consultations in order to facilitate more informed and active patient involvement in treatment decision-making. "Splitting" decision-making over at least two consultations reportedly encouraged patients to be more informed about, and clearer on their preferences for treatment decision-making. Of note, this strategy maps onto Elwyn et al.'s (2012) three key steps of SDM for clinical practice: choice talk, option talk, and decision talk, which are linked by ongoing deliberation occurring outside clinical consultations via discussion with others and information/decision-support resources. Importantly, this strategy, which has previously been advocated as an effective strategy in the medical setting, potentially addresses a number of decision-making challenges also identified by the sample (see Table 4 ). Structuring consultations allows patients the time to process information before reaching a decision, and helps clinicians more optimally schedule when final treatment decisions are made. In this way, clinicians can balance the need to act promptly to restore positive mental health and need to have a well thought out and accepted decision. Thus, impulsive and/or reactive decisions and decisional regret might be avoided.
Allowing Deliberation of Treatment Options Outside Consultations
Encouraging patients to deliberate on treatment options between consultations reportedly increased the likelihood of involving family involvement in information gathering and treatment discussions. Given that family rarely attend consultations (Drapalski, Leith, & Dixon, 2009) , involving family during post-consultation discussions gives them the opportunity to contribute to treatment preferences prior to reaching a final treatment decision. Indeed, patients appreciate when family act as a sounding board for treatment discussions outside consultations , whilst engaging family helps to mobilise them as effective supports and partners in illness management and to facilitate patient autonomy (Laidsaar-Powell et al., 2016a) . Finally, structuring decisionmaking over multiple consultations may compensate for short consultation times, a common systemic barrier (Morant, Kaminskiy, & Ramon, 2015; Simmons et al., 2013 ) that was associated with poorer decision quality in this study (i.e., more clinician-led, "prescriptive" decision-making and potentially/reportedly lower patient satisfaction with decision-making).
Supplementing Clinician Psycho-education with Patient Information Resources
Providing patients with information about their illness and treatment options emerged as a key decision-support strategy. Both clinician-provided psycho-education and written patient information resources (e.g., factsheets, recommended websites) reportedly facilitated the decision-making process by addressing a number of clinician-reported barriers (see Table 4 ). Specifically, written patient information resources were perceived as helping patients to: reconsider preconceived treatment preferences, make more efficient use of short consultations, and better understand their treatment options/preferences rather than deferring to clinician expertise. As patients were able to consult these resources outside consultations, patients arrived better prepared to initiate treatment discussions, which results in greater integration of patient preferences into treatment decisions in mental health (Matthias, Salyers, Rollins, & Frankel, 2012) . Additionally, written patient information resources may benefit clinicians' in-consultation, by facilitating clearer and more structured treatment discussions with patients, and by identifying gaps in patient knowledge about treatment options, which are seldom assessed .
Improving Patient Information Resources
Acknowledging that many patients still lacked a comprehensive understanding of treatment options, effects, and longer-term outcomes, clinicians identified priorities for future decisionsupport resources. These included: comprehensive and easy-tounderstand, evidence-based information that is specific to BPII, and covers a broad spectrum of treatments (medication and psychological-based) options and outcomes. These priorities align with well-established recommendations in the literature for patient information resources (Coulter, Entwistle, & Gilbert, 1999) . Clinicians also endorsed the inclusion of valuesclarification exercises, which are a key component of patient decision-aids and may facilitate better alignment between patient preferences and treatment choice, as in depression and schizophrenia (Stacey et al., 2014) .
Fostering the Therapeutic Relationship
Consistent with clinicians placing a high value of patientcentredness and involvement, many endorsed the therapeutic relationship as integral to effective treatment decision-making. This supports other findings that successful adaptation of SDM to chronic care (Montori, Gafni, & Charles, 2006) and mental health (Hamann & Heres, 2014; Maassen, Schrevel, Dedding, Broerse, & Regeer, 2016) settings requires greater emphasis on partnership-building and the therapeutic relationship. Critically, a therapeutic relationship founded on mutual trust reportedly alleviated patient-clinician disagreement over treatment and made patients with acute symptoms more comfortable deferring decision-making responsibility to clinicians. Indeed, patient trust is seen by psychiatrists as a "prerequisite" for SDM (Hamann et al., 2015) . Thus, fostering the therapeutic relationship in BPII may counteract unsupportive clinician behaviours (e.g., being overly directive/coercive, authoritarian), and support better continuity of care through better treatment engagement (Berk et al., 2004) .
Facilitating Family Involvement
In addition to patient involvement, several clinicians also acknowledged the importance of family involvement in treatment decision-making. Encouraging and facilitating family involvement, especially within consultations, may overcome a number of barriers to treatment decision-making (see Table 4 ). First, family provision of informational support within consultations may be of particular benefit when patients are symptomatic and cannot communicate their treatment preferences as effectively (Sajatovic et al., 2008) . Second, having family attend consultations and serve as "a second pair of ears" (LaidsaarPowell, Butow, Bu, Fisher, & Juraskova, 2016b; LaidsaarPowell et al., 2016a ) may foster better continuity of care through improved communication of information between clinicians. Lastly, involving family within consultations may strengthen their support of treatment decisions by permitting clinicians to educate family about BPII illness and the rationale for treatment options, and for family to express their treatment preferences and clarify any concerns (Drapalski et al., 2009) . Given that clinicians linked family involvement to BPII patient outcomes, both positive (e.g., improved treatment adherence) and negative (e.g., premature discontinuation of medication), ensuring family are informed and involved, to the extent desired by patients, is important. Although clinicians uniformly endorsed some views of treatment decision-making, it was evident that clinician views varied depending on their professional background (medical vs clinical psychologist), preferences for patient involvement in decision-making and level of expertise/specialty treating BPII patients. For example, clinicians with a preference for patientled decision-making were more likely to identify inadequacies in available patient information, and endorse a patient decision-making resource. Further, clinicians specialised in bipolar disorders were more likely to structure their consultations in order to optimise decision-making, and actively encourage family involvement in decision-making. These clinician-related factors have not been systematically explored within other qualitative studies of clinician views in depression (McMullen, 2012; Simmons et al., 2013) and schizophrenia (Farrelly et al., 2016; Seale et al., 2006) . These findings highlight the importance of inter-professionalism in mental health (Morant et al., 2015) , where clinicians from different backgrounds collaborate to deliver integrated patient care based on complementary expertise.
In considering these findings, a number of clinician-endorsed strategies may also be applicable to treatment decision-making in bipolar I disorder. For example, fostering the therapeutic relationship and providing patients with supplementary information resources in order to facilitate (a) greater patient involvement and (b) treatment decisions that are consistent with patient treatment preferences are both reasonable goals, as bipolar I disorder is also a life-long remitting illness which relies on patient education and patient self-management. Other strategies, however, may be less applicable to bipolar I disorder, such as structuring decision-making over multiple consultations to permit deliberation outside consultations. This is because bipolar I disorder may require clinicians to act more promptly to restore mood stability, especially if a current or impending manic episode involves psychotic features. An interesting avenue for future research would be to elucidate differences between bipolar I and II disorders in terms of how clinicians approach and involve patients in treatment decision-making.
Despite this study's strengths, such as including both medical professionals and clinical psychologists, there are some limitations. First, the present clinician sample was biased towards mostly experienced clinicians, many of whom specialised in bipolar and other mood disorders. Thus, the views and experiences of clinicians in this study may not represent those of less experienced clinicians, who may be less knowledgeable about and confident in treating BPII. Second, the "opt-in" nature of clinician recruitment creates the potential for self-selection bias. Thus, the present findings may reflect the views of clinicians who are more interested in treatment decision-making in BPII. However, it is likely that those with this expertise and a preference for SDM are best placed to advise on ways to minimise the barriers towards effective decision-making in patients with BPII.
This sample of experienced, practising clinicians acknowledged that treatment decision-making in BPII is hampered by numerous barriers, which span patient-related, clinician-related, relational, systemic, and informational domains. These clinicians also proposed a number of complementary facilitators and strategies for optimising treatment decision-making in BPII, which they described within their own and others' clinical practice, and which serve to address various barriers and challenges. Whilst clinicians uniformly recognised the importance of involving patients in informed treatment decision-making, they also identified a number of challenges to active patient participation. These findings can inform the development of BPII-specific decisionsupport resources, designed to educate and involve these patients in, values-congruent decision-making about their own treatment.
